Since July 1, 2026, a temporary Medicare program has let eligible beneficiaries fill a prescription for Wegovy, Zepbound or the newer pill Foundayo for a flat $50 monthly copay — a price that exists only because the Trump administration negotiated a separate deal directly with the drugs’ manufacturers rather than running the cost through Medicare’s usual drug-pricing process. The program, called the Medicare GLP-1 Bridge, targets beneficiaries who could not get these drugs covered for weight loss under their regular Part D plan, since Medicare has historically been barred by statute from paying for weight-loss treatment at all.
What the Federal Deal Actually Covers
The agreement, announced in November 2025, set a Medicare price of $245 a month for injectable GLP-1 drugs including Ozempic, Mounjaro, Wegovy and Zepbound, with the manufacturers agreeing to cap the beneficiary’s own share at a $50 copay regardless of dose, according to the Academy of Managed Care Pharmacy’s own account of the announcement. In exchange, the administration agreed to let Medicare cover weight-loss versions of these drugs for the first time, something the agency had proposed once before under the Biden administration and then withdrawn in its own final rule for the 2026 benefit year.
That coverage went live as the Medicare GLP-1 Bridge, a pilot program Medicare’s own coverage page confirms launched July 1, 2026 and runs only through December 31, 2027. The program covers three specific products — the Wegovy injection and tablet, the Zepbound KwikPen (but not Zepbound’s single-dose vials or pens), and the newly approved Foundayo tablet — and excludes anyone already getting a GLP-1 covered through their regular Part D plan for a different approved use.
That statutory bar traces back to Medicare’s founding law, which excludes drugs used for weight loss from the categories Part D is required to cover. Reinterpreting that exclusion administratively, rather than through an act of Congress, is exactly what the Biden administration attempted and what the Trump administration’s own final rule for the 2026 benefit year rejected — only to reverse course months later once the manufacturer price concessions made the arithmetic more favorable to a temporary, narrowly defined pilot instead of a permanent coverage expansion.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
Who Qualifies for the $50 Price
Eligibility runs on body mass index and, for some applicants, a qualifying health condition rather than income or age beyond the Medicare minimum. A beneficiary with a BMI of 35 or higher qualifies automatically; a BMI of 30 or higher qualifies with at least one condition such as heart failure, uncontrolled high blood pressure or advanced chronic kidney disease; and a BMI of 27 or higher qualifies with prediabetes, a prior heart attack or stroke, or peripheral artery disease. A prescribing doctor must certify the beneficiary is also following a diet-and-exercise program and submit a prior authorization before the pharmacy can charge the $50 rate.
The requirement that a beneficiary lack existing obesity-drug coverage is what gives the program its practical reach: someone already receiving a GLP-1 through their Part D plan for type 2 diabetes, sleep apnea or fatty liver disease keeps paying that plan’s normal cost-sharing and is not eligible for the Bridge program’s $50 rate for the same drug. The distinction means two people taking an identical dose of Wegovy can pay very different amounts depending on which condition their doctor listed as the reason for the prescription.
The Copay’s Limits and What Happens After 2027
The $50 copay comes with tradeoffs that make it less generous than it first appears. It does not count toward a beneficiary’s Part D deductible or the $2,100 annual out-of-pocket cap, cannot be reduced further through the Extra Help low-income subsidy, and cannot be spread across months using the Medicare Prescription Payment Plan the way other drug costs can. For a beneficiary living on a fixed Social Security check, a flat $50 a month is still real money even if it looks small next to the roughly $1,000 cash price these drugs carry without any government or manufacturer discount.
The program was initially planned to run just six months before a permanent replacement took over, but not enough insurers agreed to the longer-term structure by CMS’s own deadline, so the agency extended the Bridge program to eighteen months instead, pushing its end date to December 2027. What replaces it, if anything, remains an open question tied to how many beneficiaries use the program and how much it ultimately costs Medicare — a bill the government has not yet disclosed.
The arrangement sits alongside a separate, ongoing negotiation between Medicare and manufacturers over the standard price of these same drugs when prescribed for diabetes rather than weight loss, a process running on its own statutory timeline that has nothing to do with the Bridge program’s temporary authority. Nothing about the current deal guarantees that a beneficiary approved for the $50 rate today will still have access to it once the pilot expires at the end of 2027.
For now, the deal stands as one of several agreements the administration has struck directly with drugmakers this year, following similar most-favored-nation arrangements with Pfizer, AstraZeneca and EMD Serono, and it remains the only one of those deals that changed what Medicare itself will cover rather than simply lowering a cash price for people paying out of pocket.
This article was drafted with AI assistance and edited for accuracy.
More Financial Reading
